An early-stage investment and development firm located in the USA has more than $300 million in assets and operates under an evergreen structure. The firm is flexible in investment size and structure, but prefer initial investments in the $1-5M range and the firm reserves additional funds for the subsequent funding of successful companies.

The firm invests in medical devices and research tools. For medical devices, the firm prefers those that can be approved under PMA guidelines. For research tools, the firm invests in technologies that enhance and enable the discovery and manufacture of therapeutics and diagnostics.

The firm seeks to invest in small, early-stage companies with a lean but strong and qualified management/execution team. The firm prefers to invest in companies in the U.S., but will consider opportunities in Europe, Israel and Australia.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A US-based VC fund founded in 2016 and based in is investing out of a $261M fund. Within the life sciences, the firm is interested in therapeutics, medical devices, digital health and healthcare IT companies. The firm generally invests in Series B and later rounds and can invest anywhere from $1-20M in the initial check, and may participate in follow-on rounds. The firm is generally focused on investing in companies based in North America but will consider global companies if they have a large presence in the US and are focused on the US market.

The firm will invest in therapeutics, medical devices, digital health and healthcare IT companies. Within therapeutics, the firm is seeking companies in IND or later stages. In addition, the firm is interested in platform technologies, and will also invest in AI or machine learning-based drug discovery companies. The firm will not invest in single asset or single modality companies. For medical devices, the firm primarily invests in 510K pathway devices that are FDA approved. For digital health and healthcare IT companies, the firm is primarily focused on companies with B2B services, and will not invest in digital therapeutics.

The firm is willing to lead or co-invest, but will generally take a board seat if they lead the investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A digital health investment company was launched by a leading pharmaceutical company in 2016. The firm focuses on the digital health space and invest in companies that use data and intelligence derived from data to solve important healthcare problems. The firm’s investments range dependent on the opportunity and focus mainly on Series A rounds. For earlier stage companies, the firm has the ability to both lead and co-invest. The firm focuses on companies based in the U.S., but is open to investing globally.

The firm focuses on digital health technologies and solutions that aim to improve the quality and the delivery of patient care. The firm is especially interested in technology with a software component, such as those that control patient care through monitoring medications and therapies, as well as technology with a big data component. The firm will only look at devices if they have an information component and/or generate data, and is interested in technology with machine-learning applications. Based on all the criteria, the firm is indication agnostic.

The firm is a very active investor that seeks to be fully involved in their portfolio companies. The firm will take a board seat after the investment and will help companies fill management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital firm based in Taiwan is investing in breakthrough technologies changing healthcare. The firm invests from seed-Series A and the fund’s LP’s include groups in the healthcare sector.

The firm invests in early-stage life science startups with a focus on breakthrough technologies and sciences in healthcare. This includes genomic and synthetic biology technologies, digital health, ML/AI, therapeutics and diagnostics. The firm focuses on pre-IND assets in therapeutics. For technologies regulated as medical devices, the firm focuses on smart medical devices in the pre-commercial stage.

The firm have a strong clinical perspective and has the capability to help portfolio companies develop clinical resources, and has helped academic scientists form companies to commercialize their discoveries.

If you are interested in more information about this investor and other investors tracked by LSN, please email 4dmeetsai@lifesciencenation.com.

A venture capital firm based in USA has about one third of their investments in healthcare. The firm is a fairly opportunistic investor, and looks for companies that have a strong IP position and a strong management team. The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies, but they get most excited about companies leveraging new technologies and/or with the potential for platform business models.  The firm generally invests in seed-series A rounds , investing $500k-3M in rounds generally in the range of $2 to $15 million. The firm prefers to invest companies that have some clinical data. The firm will invest globally, but prefers to invest in companies based in the US.

The firm invests opportunistically in therapeutics, medical devices, diagnostics and, to a lesser degree, digital health technologies. Historically, the firm has invested in health technologies driven by breakthroughs in AI, materials science or nanotechnology, and will not invest in a digital technology that does not have strong IP. The firm is generally agnostic to indication. The firm generally does not invest in consumer-facing/telehealth-related digital health companies.

The firm looks for companies with strong IP and management teams. The firm is willing to lead or co-invest, but will generally not participate in rounds larger than $30M. When acting as a lead investor, the firm is a very active investor, and plays a large role in helping company development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early-stage venture capital firm based in Taiwan was formed by a group of successful entrepreneurs, and specializes in incubation, seed and early venture investments in technology-heavy sectors. Typical equity allocations range from $500K to $3M in seed to series A rounds. The firm is open to either leading a financing round or joining a syndication. The firm is currently seeking opportunities from Taiwan and the United States.

Within life sciences, the firm considers medical devices, IVD tools, digital health and healthcare internet of things (IoT). Within medtech, the firm is looking for early stage projects with solid unmet medical need. On-market products are less of interest. The firm is open to all risk levels and all disease indications. The firm is also interested in material science and agricultural biotech.

The firm is an active investor. The firm can work with incomplete teams, assist companies with regulatory strategy and product definition, and help overseas businesses find manufacturing partners in Taiwan. The firm typically takes a board seat in a portfolio company for projects they led.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An impact venture capital firm dedicated to funding private, early-stage whose innovation(s) significantly help or cure patients suffering from psychiatric and/or neurological diseases. The firm will invest in Seed and Series A rounds, typically allocating $200k – 8 million USD for each deal. The firm looks for deals globally and plans to make several investments in the upcoming year immediately following the first close of the fund. The firm is willing to lead rounds or co-invest as long as the investment falls within their investment criteria.

The firm is interested in devices, digital health, therapeutics, and diagnostics companies that focus on improving the treatment or curing diseases of the central nervous system. The firm prefers technologies and therapeutics that are disease modifying and/or gain significant traction in disease symptom reduction. Technologies that improve quality of life or treatment delivery in neurological and psychiatric patient populations will also be considered.

The firm sometimes prefers to take a board seat in companies in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.